Results 11 to 20 of about 12,220,634 (288)
Membrane-Mediated Action of Phosphodiesterase 5 Inhibitors [PDF]
PharmaceuticsBackground/Objectives: Phosphodiesterase 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, activate the cyclic guanosine monophosphate pathway resulting in vascular smooth muscle relaxation.
Anna I. Malykhina +2 more
doaj +3 more sources
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives [PDF]
Pharmaceuticals, 2023 Phosphodiesterase 5 (PDE5) inhibitors presented themselves as important players in the nitric oxide/cGMP pathway, thus exerting a profound impact on various physiological and pathological processes.
Ahmed K. ElHady +3 more
doaj +4 more sources
Repurposing Phosphodiesterase-5 inhibitors as chemoadjuvants [PDF]
Frontiers in Pharmacology, 2013 Phosphodiesterase-5 (PDE5) inhibitors have shown a beneficial effect in a variety of clinical conditions, such as benign prostate hyperplasia, pulmonary arterial hypertension, female sexual arousal disorder, overactive bladder, and incontinence, Raynaud's disease, heart failure and stroke among others (Sandner et al., 2007).
Amit K. Tiwari, Zhe-Sheng eChen
doaj +3 more sources
Phosphodiesterase-5 Inhibitors: Raynaud's and Beyond
Indian Journal of Rheumatology, 2017 Phosphodiesterases (PDE) are a group of ubiquitously present enzymes involved in regulation of various cellular pathways. PDE5 acts to metabolize cyclic guanosine monophosphate (GMP).
Sanat Phatak +3 more
doaj +3 more sources
A review of phosphodiesterase type 5 inhibitors [PDF]
South African Family Practice, 2014 Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat erectile dysfunction.
N. Schellack, A. Agoro
doaj +4 more sources
Phosphodiesterase type 5 inhibitors and erectile dysfunction
South African Family Practice, 2010 Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management
Catherine Whittaker
doaj +2 more sources
Phosphodiesterase Inhibitors: Present and Future
Barcelona Respiratory Network Reviews, 2023 Phosphodiesterase (PDE) inhibitors act on specific phosphodiesterase enzymes (fundamentally 3, 4 and 5), which are characterized by their expression in different organs.
José L. Izquierdo-Alonso
doaj +2 more sources
Phosphodiesterase-5 inhibitors for erectile function rehabilitation in patients undergoing nerve sparing radical prostatectomy: a scoping review [PDF]
Revista do Colégio Brasileiro de CirurgiõesIntroduction: The aim of this study was to conduct a scoping review on the efficacy of phosphodiesterase-5 inhibitors (PDE-5Is) in rehabilitating erectile function in patients undergoing cavernous nerve sparing radical prostatectomy (NSRP).
GABRIEL CARVALHO ANDRADE GADELHA +1 more
doaj +2 more sources
Cardiac Uses of Phosphodiesterase-5 Inhibitors [PDF]
Journal of the American College of Cardiology, 2012 Phosphodiesterase-5 inhibitors (PDE5Is) improve erectile function by enhancing nitric oxide availability in the penis and its supplying vasculature, resulting in vasodilation and increased blood flow. PDE5Is might benefit cardiovascular diseases because phosphodiesterase-5 is also located elsewhere in the body, including the pulmonary and systemic ...
Schwartz, Bryan G. +4 more
openaire +3 more sources
Cardiovascular Effects of Phosphodiesterase Type 5 Inhibitors
The Journal of Sexual Medicine, 2009 ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors are widely used as first-line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an increasing understanding of cyclic guanosine monophosphate (cGMP)-regulated mechanisms have triggered a number of attempts to
Charalambos, Vlachopoulos +3 more
core +4 more sources